A Blog from the Lymphoma Program at Weill Cornell Medicine and NewYork-Presbyterian
In this video from the ASCO Post, Lymphoma Program Director, Dr. John Leonard discusses results presented at the 2015 meeting of the American Society of Hematology from the recently completed Pyramid trial. This multi-center phase II study sought to determine whether R-CHOP was more effective with or without bortezomib in patients with untreated non-germinal center B-cell-like subtype diffuse large cell lymphoma. (non-GCB DLBCL)
The study’s full abstract can be read here.
This Phase 1/2 trial was designed to evaluate the safety profile and efficacy of orally administered ACP-196 in patients with relapsed or refractory CLL/SLL. ACP-196 is a second generation BTK inhibitor that is more selective than the first generation BTK inhibitor ibrutinib. Bruton’s tyrosine kinase (BTK) is an enzyme involved in B cell receptor pathway signaling that has been shown to be critical for CLL cell survival. Trials with ibrutinib established BTK as an effective therapeutic target for the treatment of CLL.
As part of the trial, patients were treated continuously with escalating doses of ACP-196, once or twice daily. No dose limiting toxicities were identified and 100 mg twice daily was established as the most efficacious dose. The median age of the patients and number of prior therapies were 62 years and 3 prior therapies respectively. The median time on the study was 10.3 months. As of June 2015 there were 60 patients who were evaluable for response.
The overall response rate was 93% for all patients and 100% in the deletion 17p patient. ACP-196 was well tolerated, with 93% of patients remaining on treatment. The most common adverse events were headache and diarrhea. No disease progression has occurred to date.
Results from this study show that ACP-196 is a highly potent and selective oral BTK inhibitor with a favorable safety profile. Currently there is a Phase 3 trial comparing ACP-196 to Ibrutinib in Patients with High Risk CLL open to eligible patients at Weill Cornell Medicine.
In this video from Targeted Oncology, Lymphoma Program Director, Dr. John Leonard discusses the top lymphoma studies presented during the 57th annual meeting of the American Society of Hematology in Orlando, Florida.
In addition to this video, Dr. Leonard also continued his now annual tradition of picking 10 noteworthy lymphoma abstracts released before the meeting in his #LeonardList. As he explained the criteria for picking abstracts on the list:
“I scan all the lymphoma-related abstracts, focusing less on the biology and more on the therapy. I look at both oral and poster abstracts because I think people might miss posters that are of interest and worth highlighting. And I focus on ideas I think are either practice changing, or intriguing, or ‘out of the box,’ that people might otherwise not see.”
